Palatin to Begin Trading on Nasdaq Stock Exchange
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies Q2 Earnings Call Highlights
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Palatin Announces 1-for-50 Reverse Stock Split
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Technologies Announces Closing of Reduced Public Offering
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
Palatin Technologies Announces Pricing of up to $23 Million Public Offering
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Palatin Appeals NYSE American Notice of Delisting
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Palatin Receives Notice of Non-Compliance from NYSE American
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones